taug_logo_f_improf_179x131Tauriga Sciences, Inc is a diversified biotechnology company that entered the marijuana industry this year. It made its entry by acquiring the medical cannabis manufacturer Honeywood LLC, which became one of Tauriga’s subsidiary companies.

Tauriga was founded in 2001 and has since gone through different businesses and names. Among these are New England Acquisitions, Atlantic Wine Agencies, and Novo Energies Corp. It finally became Tauriga Sciences, Inc in 2013.

Today, Tauriga Sciences, Inc is traded in OTC markets under the symbol TAUG. Its market cap is pegged at USD 14.6 M.

The company takes on the strategy of diversifying its portfolio through the acquisition of licenses, exclusive and non-exclusive rights, as well as entire businesses. Currently, Tauriga’s featured subsidiary companies are Microbial Robotics LLC (previously known as Bacterial Robotics LLC), Pilus Energy LLC, and on the marijuana front, Honeywood LLC.

Microbial Robotics LLC is a firm that bio-engineers certain micro-organisms to ‘program’ them into microscopic robots. Such micro robots are deemed useful in various applications including disease reduction, water cleaning, food cultivation, fuel production, and therapeutics production.

Pilus Energy is a subsidiary of Microbial Robotics and it has also been acquired by Tauriga Sciences. It is also a biotech firm, with a specialty in genetically engineering certain bacteria. The bacteria process wastewater to produce direct current electricity and several useful gases and chemicals.

Lastly, Tauriga’s subsidiary in the medical cannabis space, which it acquired in March 2014, is Honeywood LLC. This subsidiary develops and sells topical cannabis products such as healing creams and skin lotions. It sells these products through online channels under the Doc Greens brand.

At the helm of Tauriga Sciences is Dr. Stella Sung, the company’s CEO, Chairman, COO, and Interim CFO. With her are VP for Strategic Planning Seth M. Shaw, Chief Medical Officer Dr. Lawrence A. May, and Operations Manager Ghalia Lahlou. Other executives include the VP and General Manager of Pilus Energy Ian Harrison, and VP of NuclearBot Development David Schweizer.


Yahoo! Finance: TAUG News

Latest Financial News for TAUG

Tauriga Sciences, Inc. Receives Approval From Credit Card Processor to Increase Individual E-Commerce Transaction Limit to $3,000 USD

The Company Continues to Generate Strong Results From Its Highest Margin E-Commerce Business Segment NEW YORK, NY, Aug. 11, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of functional “supplement” chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as two ongoing Biotechnology initiatives, today announced that it has received approval from its credit card processor (“T1 Payments”) to increase the individual E-Commerce transaction processing limit to $3,000 USD.  Individual E-Commerce orders that are greater than $3,000 USD will continue to be paid, to the Company, via wire transfer (there have been several, thus far, this Quarter).    ABOUT TAURIGA SCIENCES INC.Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives.  The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment.  The main product line, branded as Tauri-Gum™, consists of a proprietary supplement chewing gum that is both Kosher certified and Vegan formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate) & (CBG Infused Tauri-Gum™ Flavor: Peach-Lemon).  The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at http://www.tauriga.comComplementary to the Company’s retail business, are its two ongoing biotechnology initiatives.  The first one relates to the development of a Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed to help patients that are subjected to ongoing chemotherapy treatment).  On March 18, 2020, the Company announced that it filed a provisional U.S. patent application covering its pharmaceutical grade version of Tauri-Gum™.  The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”.  The second one relates to a collaboration agreement with Aegea Biotechnologies Inc. for the co-development of a rapid, multiplexed, Novel Coronavirus (COVID-19) test with superior sensitivity and selectivity.   The Company is headquartered in New York City and operates a regional office in Barcelona, Spain.  In addition, the Company operates a full time E-Commerce fulfillment center located in LaGrangeville, New York.           DISCLAIMER -- Forward-Looking Statements This press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in  forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements.Contact:CONTACT INFORMATION Tauriga Sciences, Inc. 555 Madison Avenue, 5th Floor New York, NY  10022 Chief Executive Officer Mr. Seth M. Shaw Email:  sshaw@tauriga.com cell (917) 796 9926 Instagram: @taurigum Twitter: @SethMShaw Corp. Website:   www.tauriga.com E-Commerce Website:  www.taurigum.com

Tauriga Sciences, Inc.’s E-Commerce Fulfillment Center Confirms Arrival of Black Currant Flavor Tauri-Gum Inventory

Tauriga Sciences Crate of Black Currant Tauri-Gum™ Arrives at E-Commerce Fulfillment CenterCurrant Flavor Tauri-Gum™ is Cannabigerol Infused - Each Piece of Chewing Gum Contains 15mg CBGNEW YORK, NY, Aug. 06, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of functional “supplement” chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as two ongoing Biotechnology initiatives, today announced the arrival of Black Currant flavor Cannabigerol (“CBG”) infused Tauri-Gum™ inventory – at its E-Commerce fulfillment center.  This product is the Company’s second CBG version of Tauri-Gum™ and is now available on the Company’s E-Commerce website (www.taurigum.com).  Each piece of Black Currant chewing gum contains 15mg CBG isolate – MSRP: $21.99 per Blister Pack.Link to Black Currant CBG Tauri-Gum™ – E-Commerce Store: https://taurigum.com/products/black-currant-cbd-gum-retail-boxInitial Production Run:  Approximately 8,600 Blister Packs (860 Retail Boxes)The Company has been experiencing strong levels of interest in its Black Currant flavor Tauri-Gum™ product, from a broad array of potential customers and retailers.  The product is Kosher Certified, Vegan Formulated, Lab Tested, NON-GMO, Allergen Free, Gluten Free, NO THC, and 100% Made in the USA  ABOUT TAURIGA SCIENCES INC.Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives.  The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment.  The main product line, branded as Tauri-Gum™, consists of a proprietary supplement chewing gum that is both Kosher certified and Vegan formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate) & (CBG Infused Tauri-Gum™ Flavor: Peach-Lemon).  The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at www.tauriga.comComplementary to the Company’s retail business, are its two ongoing biotechnology initiatives.  The first one relates to the development of a Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed to help patients that are subjected to ongoing chemotherapy treatment).  On March 18, 2020, the Company announced that it filed a provisional U.S. patent application covering its pharmaceutical grade version of Tauri-Gum™.  The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”.  The second one relates to a collaboration agreement with Aegea Biotechnologies Inc. for the co-development of a rapid, multiplexed, Novel Coronavirus (COVID-19) test with superior sensitivity and selectivity.   The Company is headquartered in New York City and operates a regional office in Barcelona, Spain.  In addition, the Company operates a full time E-Commerce fulfillment center located in LaGrangeville, New York.DISCLAIMER -- Forward-Looking StatementsThis press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in  forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements.Contact:CONTACT INFORMATION Tauriga Sciences, Inc. 555 Madison Avenue, 5th Floor New York, NY  10022 Chief Executive Officer Mr. Seth M. Shaw Email:  sshaw@tauriga.com cell (917) 796 9926 Instagram: @taurigum Twitter: @SethMShaw Corp. Website:   www.tauriga.com E-Commerce Website:  www.taurigum.comAttachment * Tauriga Sciences

Tauriga Sciences, Inc. Generates Record Monthly E-Commerce Sales for the Month of July 2020

825am EST Monday Morning PR 100+DPI E-Commerce Snapshot: Rainbow Deluxe Sampler Pack  The Company Has Reported Its 5thConsecutive Month of Record Results From Its Highest Margin E-Commerce Business SegmentNEW YORK, NY, Aug. 03, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of functional “supplement” chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as two ongoing Biotechnology initiatives, today announced that it has established a new monthly record - July 2020 - with respect to its E-Commerce sales.  For the 5thconsecutive month (during July 2020), the Company has generated record results from its highest margin E-commerce business segment.  During July 2020, monthly E-Commerce grew by 50%+ on a sequential Month to Month basis. Additionally, the Company is off to a strong start for the month of August 2020. The Company is excited about the upcoming launch of its newest product offering: Rainbow Deluxe Sampler Pack (“Rainbow Pack” or “Pack”).  The Rainbow Pack is available exclusively on the Company’s E-Commerce website (www.taurigum.com) – priced @ $99.99 per Pack.The Company is now pre-selling its Rainbow Deluxe Sampler Pack on its E-Commerce Website.  Each Rainbow Pack contains 1 Blister Pack of each of the 6 distinct Tauri-Gum™ flavors/versionsLink:  https://taurigum.com/products/rainbow-deluxe-sampler-packABOUT TAURIGA SCIENCES INC.Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives.  The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment.  The main product line, branded as Tauri-Gum™, consists of a proprietary supplement chewing gum that is both Kosher certified and Vegan formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate) & (CBG Infused Tauri-Gum™ Flavor: Peach-Lemon).  The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at www.tauriga.comComplementary to the Company’s retail business, are its two ongoing biotechnology initiatives.  The first one relates to the development of a Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed to help patients that are subjected to ongoing chemotherapy treatment).  On March 18, 2020, the Company announced that it filed a provisional U.S. patent application covering its pharmaceutical grade version of Tauri-Gum™.  The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”.  The second one relates to a collaboration agreement with Aegea Biotechnologies Inc. for the co-development of a rapid, multiplexed, Novel Coronavirus (COVID-19) test with superior sensitivity and selectivity.   The Company is headquartered in New York City and operates a regional office in Barcelona, Spain.  In addition, the Company operates a full time E-Commerce fulfillment center located in LaGrangeville, New York.   DISCLAIMER -- Forward-Looking Statements This press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in  forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements.Contact:CONTACT INFORMATION Tauriga Sciences, Inc. 555 Madison Avenue, 5th Floor New York, NY  10022 Chief Executive Officer Mr. Seth M. Shaw Email:  sshaw@tauriga.com cell (917) 796 9926 Instagram: @taurigum Twitter: @SethMShaw Corp. Website:   www.tauriga.com E-Commerce Website:  www.taurigum.comAttachment * 825am EST Monday Morning PR 100+DPI

Tauriga Sciences, Inc. Receives Notice of Allowance from the European Union Intellectual Property Office - Registering its Trademark for Tauri-Gummies

Tauriga Sciences Notice of Allowance from European Union IPO (Trademark 018138348)NEW YORK, NY, Aug. 03, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of functional “supplement” chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as two ongoing Biotechnology initiatives, today announced that it has received a Notice of Allowance from the European Union Intellectual Property Office (“E.U.I.P.O.”) granting the Company its trademark Registration for: Tauri-Gummies™ (E.U. Trademark 018138348).  The effective registration date, granting this Tauri-Gummies™ trademark to the Company, was June 24, 2020. The first period of protection ends on October 16, 2029, and may be extended thereafter for 10-year intervals.Below - Link to European Union Trademark Website:  https://euipo.europa.eu/eSearch/basic/1+1+1+1/tauri-gumThe Company believes that the allowance of this European Union Trademark materially enhances the global value of its important brand: Tauri-Gummies™.  Previously, on February 21, 2020, the Company announced that it had received a Notice of Allowance from the European Union Intellectual Property Office - Granting the Company its trademark Registration for its flagship brand: Tauri-Gum™ (E.U. Trademark 018138334).ABOUT TAURIGA SCIENCES, INC.Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives. The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment.  The main product line, branded as Tauri-Gum™, consists of a proprietary supplement chewing gum that is both Kosher certified and Vegan formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate) & (CBG Infused Tauri-Gum™ Flavor: Peach-Lemon). The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at www.tauriga.com. Complementary to the Company’s retail business, are its two ongoing biotechnology initiatives.  The first one relates to the development of a Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed to help patients that are subjected to ongoing chemotherapy treatment).  On March 18, 2020, the Company announced that it filed a provisional U.S. patent application covering its pharmaceutical grade version of Tauri-Gum™. The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”. The second one relates to a collaboration agreement with Aegea Biotechnologies Inc. for the co-development of a rapid, multiplexed, Novel Coronavirus (COVID-19) test with superior sensitivity and selectivity.   The Company is headquartered in New York City and operates a regional office in Barcelona, Spain.  In addition, the Company operates a full time E-Commerce fulfillment center located in LaGrangeville, New York.DISCLAIMER -- Forward-Looking StatementsThis press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in forward-looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements.CONTACT INFORMATION Tauriga Sciences, Inc. 555 Madison Avenue, 5th Floor New York, NY 10022 Chief Executive Officer Mr. Seth M. Shaw Email: sshaw@tauriga.com cell (917) 796 9926 Instagram: @taurigum Twitter: @SethMShaw Corp. Website: www.tauriga.com E-Commerce Website: www.taurigum.com Attachment * Tauriga Sciences

Tauriga Sciences, Inc. Now Pre-Selling Its Rainbow Deluxe Sampler Pack Exclusively on Its E-Commerce Website

Each Rainbow Deluxe Sampler Pack Contains One Blister Pack of Each of the Six Distinct Tauri-Gum™ Flavors/Versions NEW YORK, NY, July 28, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of functional “supplement” chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as two ongoing Biotechnology initiatives, today announced that it is now Pre-Selling its propriety Rainbow Deluxe Sampler Pack (“Rainbow Pack”) exclusively on its E-Commerce Website (www.taurigum.com).  The Company has assembled a multi-faceted and diverse marketing initiative to support the upcoming – Official Launch – of this important new product offering.  Each Rainbow Pack carries an MSRP of $99.99and there will be a special packaging component for customers to enjoy.Link:  https://taurigum.com/products/rainbow-deluxe-sampler-packThe Official Rainbow PackProduct Launch is expected to commence during the first two weeks of August 2020.Separately, the Company is planning to issue a press release on Monday August 3, 2020 to disclose the performance of its highest margin E-Commerce business segment – for the Month of July 2020.  The Company continues to experience impressive levels of growth and overall strength – with respect to this most important business segment.ABOUT TAURIGA SCIENCES INC.Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives.  The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment.  The main product line, branded as Tauri-Gum™, consists of a proprietary supplement chewing gum that is both Kosher certified and Vegan formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate) & (CBG Infused Tauri-Gum™ Flavor: Peach-Lemon).  The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at www.tauriga.comComplementary to the Company’s retail business, are its two ongoing biotechnology initiatives.  The first one relates to the development of a Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed to help patients that are subjected to ongoing chemotherapy treatment).  On March 18, 2020, the Company announced that it filed a provisional U.S. patent application covering its pharmaceutical grade version of Tauri-Gum™.  The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”.  The second one relates to a collaboration agreement with Aegea Biotechnologies Inc. for the co-development of a rapid, multiplexed, Novel Coronavirus (COVID-19) test with superior sensitivity and selectivity.   The Company is headquartered in New York City and operates a regional office in Barcelona, Spain.  In addition, the Company operates a full time E-Commerce fulfillment center located in LaGrangeville, New York.DISCLAIMER -- Forward-Looking Statements This press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in  forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements.Contact:CONTACT INFORMATION Tauriga Sciences, Inc. 555 Madison Avenue, 5th Floor New York, NY  10022 Chief Executive Officer Mr. Seth M. Shaw Email:  sshaw@tauriga.com cell (917) 796 9926 Instagram: @taurigum Twitter: @SethMShaw Corp. Website:   www.tauriga.com E-Commerce Website:  www.taurigum.com